Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Control Bionics Ltd. ( (AU:CBL) ) has shared an update.
Control Bionics Limited will host an investor webinar on 26 February 2026, following the release of its interim financial report and Appendix 4D, with CEO Jeremy Steele and CFO Shannon Boothroyd presenting a business update and taking questions from investors. The briefing underscores ongoing execution around its NeuroNode assistive communication platform and the commercial rollout of its miniaturised NeuroStrip EMG device, which together position the company to deepen its presence in assistive technologies while opening new diagnostic and performance markets for stakeholders.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
More about Control Bionics Ltd.
Control Bionics Limited is an Australian medical device company specialising in surface electromyography (EMG) technology, with more than two decades of experience in developing assistive communication solutions. Its core patented NeuroNode device is a wireless wearable that captures minute EMG signals to enable speech and computer control, integrating touch, eye-gaze and NeuroNode inputs to help patients communicate faster and with less fatigue across markets in North America, Australia, Singapore and Japan. The company is also commercialising NeuroStrip, a miniaturised EMG wearable aimed at expanding into new segments such as health diagnostics, sports performance and rehabilitation.
Average Trading Volume: 488,307
Technical Sentiment Signal: Buy
Current Market Cap: A$25.13M
See more insights into CBL stock on TipRanks’ Stock Analysis page.